Abivax's Ulcerative Colitis Data Boosts Analyst Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 01 2026
0mins
Source: CNBC
- Analyst Upgrade: Jefferies analyst Faisal Khurshid upgraded Abivax from hold to buy, raising the price target from $108 to $158, indicating an 18% upside from Tuesday's close, reflecting strong confidence in the company's future performance.
- Positive Clinical Data: New data shows that malignancy rates for Abivax's obefazimod treatment in ulcerative colitis patients are in line with normal levels, with over a third of initially non-responding patients achieving remission after about 10 months, indicating both efficacy and safety of the treatment.
- Strong Stock Reaction: Abivax shares surged 39% on Tuesday, marking its best performance since July 23, 2025, reflecting a positive market reaction to the new data and a restoration of investor confidence.
- Optimistic Market Outlook: While analysts note ongoing risks related to cash runway and commercial needs, the strengthening efficacy profile with accumulating data raises expectations for Abivax's potential standalone launch in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 143.990
Low
131.00
Averages
150.71
High
175.00
Current: 143.990
Low
131.00
Averages
150.71
High
175.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three High-Potential Stocks: Abivax, Krystal Biotech, and Marvell
- Strong Performance of Abivax: Abivax's stock has surged over 1,500% in the past 12 months, primarily due to the impressive efficacy of its candidate drug obefazimod for ulcerative colitis, with an expected application for approval by the end of 2026 that could significantly enhance its market share.
- Financial Growth of Krystal Biotech: Krystal Biotech's Vyjuvek generated $116.4 million in revenue in Q1, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong demand and profitability in the rare disease market.
- Market Demand for Marvell Technology: Marvell Technology reported a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and is expected to benefit from increasing demand for ASICs as AI infrastructure spending grows.
- Future Growth Potential: All three companies exhibit strong growth potential, with Abivax and Krystal Biotech driving future performance through innovative drug development, while Marvell is well-positioned to capitalize on the expansion of the AI market, potentially delivering market-beating returns.
See More
Abivax, Krystal Biotech, and Marvell's Market Potential
- Abivax's Clinical Progress: Abivax's shares have surged over 1,500% in the past 12 months, driven by strong efficacy results of its candidate obefazimod for ulcerative colitis, with an application for approval expected by the end of 2026, potentially carving out a niche in a competitive market.
- Krystal Biotech's Financial Performance: In Q1, Krystal Biotech reported revenue of $116.4 million, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong market demand and profitability in treating rare diseases, with further growth anticipated.
- Marvell's Market Demand: Marvell Technology achieved a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and as AI infrastructure spending rises, sales and earnings are expected to continue growing.
- Optimistic Industry Outlook: All three companies exhibit strong growth potential in their respective fields, with Abivax and Krystal Biotech's innovative drugs and Marvell's custom chips likely to deliver significant market returns in the coming years, attracting investor interest.
See More
Abivax Completes $920M Public Offering with Full Underwriter Option Exercise
- Offering Expansion: Abivax's U.S. public offering saw underwriters fully exercise their option for an additional 960K American Depositary Shares (ADSs), bringing the total offering to 7.36 million ADSs, with expected gross proceeds of approximately $920 million and net proceeds of $874.1 million, indicating strong market support for its financing needs.
- Pricing Strategy: The additional ADSs were priced at $125 each, equivalent to €109.71 per ordinary share based on the European Central Bank's June 30 exchange rate, matching the volume-weighted average price of Abivax's ordinary shares on Euronext Paris over the preceding three trading days, reflecting investor confidence in the company's valuation.
- Clear Use of Proceeds: Abivax plans to allocate the net proceeds towards clinical research and development expenses primarily related to ulcerative colitis and Crohn’s disease, as well as potential commercialization of its lead drug candidate, obefazimod, in the U.S., demonstrating the company's commitment to advancing its drug pipeline.
- Positive Market Reaction: Following the public offering announcement, ABVX shares rose 3.7% in premarket trading, indicating increased investor confidence in the company's future prospects, which may further enhance its market performance.
See More
Abivax Increases Offering to 7.36 Million Shares, Raising $874.1 Million
- Offering Expansion: Abivax has increased its offering size from an initial 6.4 million shares to 7.36 million shares, expecting to raise approximately $920 million in gross proceeds at $125 per share, with net proceeds projected at $874.1 million after underwriting fees, significantly bolstering the company's financial resources for future growth.
- Clear Use of Proceeds: The funds raised will support the potential U.S. commercialization of its lead drug candidate, Obefazimod, fund clinical research and development programs primarily focused on ulcerative colitis and Crohn's disease, and cover general corporate purposes, demonstrating the company's commitment to drug development.
- Positive Clinical Trial Results: Recent Phase 3 trial results for Obefazimod revealed that 37.2% of patients who did not respond to initial therapy achieved clinical remission, while increasing the dose helped 45.5% of relapsed patients regain remission, further validating the drug's efficacy and safety profile.
- Optimistic Market Sentiment: Retail sentiment surrounding ABVX on Stocktwits remains in the 'bullish' territory, with increased chatter about a potential buyout, as some users anticipate the company could be acquired by the end of the year, reflecting investor confidence in the company's future prospects.
See More
Abivax Fully Exercises Underwriters' Option for Additional ADS Purchase
- Expanded Financing: Abivax has fully exercised the underwriters' option to purchase an additional 960,000 American Depositary Shares (ADSs), bringing the total gross proceeds of the offering to approximately $920 million (€807 million), significantly enhancing the company's financial strength for future growth.
- Clear Use of Proceeds: The estimated net proceeds from this offering are approximately $874.1 million (€767.1 million), which will primarily fund the development of the lead drug candidate obefazimod and clinical research related to ulcerative colitis and Crohn's disease, reflecting the company's commitment to R&D.
- Positive Market Response: The offering price for each additional ADS is set at $125, representing a 2.39% premium over the volume-weighted average price from the last three trading days, indicating strong market confidence in Abivax's growth potential, which may drive stock price appreciation.
- Strategic Planning: Abivax aims to close this offering on July 6, 2026, further solidifying its market position in the biotechnology sector and laying the groundwork for drug commercialization in the U.S., showcasing the company's proactive approach to future market opportunities.
See More
Abivax Raises $800 Million Through ADS Offering
- Increased Offering Size: Abivax announced a public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, raising the total offering size from $600 million to $800 million, reflecting strong market confidence in its drug candidate.
- Clear Use of Proceeds: The net proceeds from the offering will be allocated towards the commercialization of the lead drug candidate obefazimod in the U.S. and clinical research, effectively supporting the company's operational funding needs until Q2 2029.
- Extended Cash Runway: As of March 31, Abivax reported approximately €491.6 million in cash and cash equivalents, and with the new funding, the company expects to extend its cash runway into Q2 2029, enhancing its survival prospects in the market.
- Optimistic Market Sentiment: Despite the offering leading to an 8% dilution of share capital, retail sentiment on Stocktwits remains bullish, indicating strong confidence in Abivax's future growth potential.
See More
Three High-Potential Stocks: Abivax, Krystal Biotech, and Marvell
- Strong Performance of Abivax: Abivax's stock has surged over 1,500% in the past 12 months, primarily due to the impressive efficacy of its candidate drug obefazimod for ulcerative colitis, with an expected application for approval by the end of 2026 that could significantly enhance its market share.
- Financial Growth of Krystal Biotech: Krystal Biotech's Vyjuvek generated $116.4 million in revenue in Q1, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong demand and profitability in the rare disease market.
- Market Demand for Marvell Technology: Marvell Technology reported a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and is expected to benefit from increasing demand for ASICs as AI infrastructure spending grows.
- Future Growth Potential: All three companies exhibit strong growth potential, with Abivax and Krystal Biotech driving future performance through innovative drug development, while Marvell is well-positioned to capitalize on the expansion of the AI market, potentially delivering market-beating returns.
See More
Abivax, Krystal Biotech, and Marvell's Market Potential
- Abivax's Clinical Progress: Abivax's shares have surged over 1,500% in the past 12 months, driven by strong efficacy results of its candidate obefazimod for ulcerative colitis, with an application for approval expected by the end of 2026, potentially carving out a niche in a competitive market.
- Krystal Biotech's Financial Performance: In Q1, Krystal Biotech reported revenue of $116.4 million, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong market demand and profitability in treating rare diseases, with further growth anticipated.
- Marvell's Market Demand: Marvell Technology achieved a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and as AI infrastructure spending rises, sales and earnings are expected to continue growing.
- Optimistic Industry Outlook: All three companies exhibit strong growth potential in their respective fields, with Abivax and Krystal Biotech's innovative drugs and Marvell's custom chips likely to deliver significant market returns in the coming years, attracting investor interest.
See More
Abivax Completes $920M Public Offering with Full Underwriter Option Exercise
- Offering Expansion: Abivax's U.S. public offering saw underwriters fully exercise their option for an additional 960K American Depositary Shares (ADSs), bringing the total offering to 7.36 million ADSs, with expected gross proceeds of approximately $920 million and net proceeds of $874.1 million, indicating strong market support for its financing needs.
- Pricing Strategy: The additional ADSs were priced at $125 each, equivalent to €109.71 per ordinary share based on the European Central Bank's June 30 exchange rate, matching the volume-weighted average price of Abivax's ordinary shares on Euronext Paris over the preceding three trading days, reflecting investor confidence in the company's valuation.
- Clear Use of Proceeds: Abivax plans to allocate the net proceeds towards clinical research and development expenses primarily related to ulcerative colitis and Crohn’s disease, as well as potential commercialization of its lead drug candidate, obefazimod, in the U.S., demonstrating the company's commitment to advancing its drug pipeline.
- Positive Market Reaction: Following the public offering announcement, ABVX shares rose 3.7% in premarket trading, indicating increased investor confidence in the company's future prospects, which may further enhance its market performance.
See More
Abivax Increases Offering to 7.36 Million Shares, Raising $874.1 Million
- Offering Expansion: Abivax has increased its offering size from an initial 6.4 million shares to 7.36 million shares, expecting to raise approximately $920 million in gross proceeds at $125 per share, with net proceeds projected at $874.1 million after underwriting fees, significantly bolstering the company's financial resources for future growth.
- Clear Use of Proceeds: The funds raised will support the potential U.S. commercialization of its lead drug candidate, Obefazimod, fund clinical research and development programs primarily focused on ulcerative colitis and Crohn's disease, and cover general corporate purposes, demonstrating the company's commitment to drug development.
- Positive Clinical Trial Results: Recent Phase 3 trial results for Obefazimod revealed that 37.2% of patients who did not respond to initial therapy achieved clinical remission, while increasing the dose helped 45.5% of relapsed patients regain remission, further validating the drug's efficacy and safety profile.
- Optimistic Market Sentiment: Retail sentiment surrounding ABVX on Stocktwits remains in the 'bullish' territory, with increased chatter about a potential buyout, as some users anticipate the company could be acquired by the end of the year, reflecting investor confidence in the company's future prospects.
See More
Abivax Fully Exercises Underwriters' Option for Additional ADS Purchase
- Expanded Financing: Abivax has fully exercised the underwriters' option to purchase an additional 960,000 American Depositary Shares (ADSs), bringing the total gross proceeds of the offering to approximately $920 million (€807 million), significantly enhancing the company's financial strength for future growth.
- Clear Use of Proceeds: The estimated net proceeds from this offering are approximately $874.1 million (€767.1 million), which will primarily fund the development of the lead drug candidate obefazimod and clinical research related to ulcerative colitis and Crohn's disease, reflecting the company's commitment to R&D.
- Positive Market Response: The offering price for each additional ADS is set at $125, representing a 2.39% premium over the volume-weighted average price from the last three trading days, indicating strong market confidence in Abivax's growth potential, which may drive stock price appreciation.
- Strategic Planning: Abivax aims to close this offering on July 6, 2026, further solidifying its market position in the biotechnology sector and laying the groundwork for drug commercialization in the U.S., showcasing the company's proactive approach to future market opportunities.
See More
Abivax Raises $800 Million Through ADS Offering
- Increased Offering Size: Abivax announced a public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, raising the total offering size from $600 million to $800 million, reflecting strong market confidence in its drug candidate.
- Clear Use of Proceeds: The net proceeds from the offering will be allocated towards the commercialization of the lead drug candidate obefazimod in the U.S. and clinical research, effectively supporting the company's operational funding needs until Q2 2029.
- Extended Cash Runway: As of March 31, Abivax reported approximately €491.6 million in cash and cash equivalents, and with the new funding, the company expects to extend its cash runway into Q2 2029, enhancing its survival prospects in the market.
- Optimistic Market Sentiment: Despite the offering leading to an 8% dilution of share capital, retail sentiment on Stocktwits remains bullish, indicating strong confidence in Abivax's future growth potential.
See More
